AAAAAA
Results:
1-12
|
Results: 12
Authors:
Para, MF
Kalish, LA
Collier, AC
Pollard, RB
Kumar, PN
Mintz, L
Wallach, FR
Drew, WL
Citation: Mf. Para et al., Qualitative and quantitative PCR measures of cytomegalovirus in patients with advanced HIV infection who require transfusions, J ACQ IMM D, 26(4), 2001, pp. 320-325
Authors:
Smith, BA
Neidig, JL
Nickel, JT
Mitchell, GL
Para, MF
Fass, RJ
Citation: Ba. Smith et al., Aerobic exercise: effects on parameters related to fatigue, dyspnea, weight and body composition in HIV-infected adults, AIDS, 15(6), 2001, pp. 693-701
Authors:
Albrecht, MA
Bosch, RJ
Hammer, SM
Liou, SH
Kessler, H
Para, MF
Eron, J
Valdez, H
Dehlinger, M
Katzenstein, DA
Citation: Ma. Albrecht et al., Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection., N ENG J MED, 345(6), 2001, pp. 398-407
Authors:
Para, MF
Kalish, LA
Collier, AC
Murphy, EL
Drew, WL
Citation: Mf. Para et al., Correlates of change in cytomegalovirus viremia in patients with advanced human immunodeficiency virus infection who require transfusion, J INFEC DIS, 183(11), 2001, pp. 1673-1677
Authors:
Murphy, EL
Collier, AC
Kalish, LA
Assmann, SF
Para, MF
Flanigan, TP
Kumar, PN
Mintz, L
Wallach, FR
Nemo, GJ
Citation: El. Murphy et al., Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease, ANN INT MED, 135(1), 2001, pp. 17-26
Authors:
Para, MF
Finkelstein, D
Becker, S
Dohn, M
Walawander, A
Black, JR
Citation: Mf. Para et al., Reduced toxicity with gradual initiation of trimethoprim-sulfamethoxazole as primary prophylaxis for Pneumocystis carinii pneumonia: AIDS Clinical Trials Group 268, J ACQ IMM D, 24(4), 2000, pp. 337-343
Authors:
Albrecht, MA
Hughes, MD
Liou, SH
Katzenstein, DA
Murphy, R
Balfour, HH
Para, MF
Valdez, H
Hammer, SM
Citation: Ma. Albrecht et al., Effect of lamivudine in HIV-infected persons with prior exposure to zidovudine/didanosine or zidovudine/zalcitabine, AIDS RES H, 16(14), 2000, pp. 1337-1344
Authors:
Demeter, LM
Shafer, RW
Meehan, PM
Holden-Wiltse, J
Fischl, MA
Freimuth, WW
Para, MF
Reichman, RC
Citation: Lm. Demeter et al., Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260), ANTIM AG CH, 44(3), 2000, pp. 794-797
Authors:
Para, MF
Glidden, DV
Coombs, RW
Collier, AC
Condra, JH
Craig, C
Bassett, R
Leavitt, R
Snyder, S
McAuliffe, V
Boucher, C
Citation: Mf. Para et al., Baseline human immunodeficiency virus type 1 phenotype, genotype, and RNA response after switching from long-term hard-capsule saquinavir to indinavir or soft-gel-capsule saquinavir in AIDS Clinical Trials Group protocol 333, J INFEC DIS, 182(3), 2000, pp. 733-743
Authors:
Sevin, AD
DeGruttola, V
Nijhuis, M
Schapiro, JM
Foulkes, AS
Para, MF
Boucher, CAB
Citation: Ad. Sevin et al., Methods for investigation of the relationship between drug-susceptibility phenotype and human immunodeficiency virus type 1 genotype with applications to AIDS Clinical Trials Group 333, J INFEC DIS, 182(1), 2000, pp. 59-67
Authors:
Para, MF
Meehan, P
Holden-Wiltse, J
Fischl, M
Morse, G
Shafer, R
Demeter, LM
Wood, K
Nevin, T
Virani-Ketter, N
Freimuth, WW
Citation: Mf. Para et al., ACTG 260: a randomized, phase I-II, dose-ranging trial of the anti-human immunodeficiency virus activity of delavirdine monotherapy, ANTIM AG CH, 43(6), 1999, pp. 1373-1378
Authors:
Triozzi, PL
Aldrich, W
Bresler, HS
Para, MF
Flancbaum, LJ
Citation: Pl. Triozzi et al., Cellular immunotherapy of advanced human immunodeficiency virus type 1 infection using autologous lymph node lymphocytes: Effects on chemokine production, J INFEC DIS, 179(1), 1999, pp. 245-248
Risultati:
1-12
|